KERF

Cyarl Danding A

Consolid Recipion

\*\*\*

Content available at: https://www.ipinnovative.com/open-access-journals

# IP International Journal of Medical Microbiology and Tropical Diseases

Journal homepage: https://www.ijmmtd.org/



#### **Review Article**

# Evaluating diagnostic approaches for diabetic foot infections: A systematic review

J Bindhu<sup>1</sup>\*o, R Umashankar<sup>2</sup>o, Ramesh Vasudevan<sup>3</sup>o, B. Mahalakshmi<sup>4</sup>, Sovan Bagchi<sup>5</sup>o, Wethroe Kapfo<sup>6</sup>o, Abida Khan<sup>7</sup>o, Suria Prabha<sup>8</sup>o, Muthu Prasanna<sup>9</sup>o

#### **Abstract**

Diabetic neuropathy, a major complication of diabetes mellitus, encompasses disorders affecting the somatic and autonomic nervous systems. Among its clinical manifestations is diabetic foot (DF), characterized by structural and functional foot changes, including ulceration, infection, and gangrene. These issues often arise from prolonged hyperglycemia, neuropathy, and peripheral vascular disease and can progress to severe complications such as foot ulcers, Charcot osteoarthropathy, and limb amputation. Diabetic foot infections (DFIs), a serious complication, impose a significant burden on global healthcare systems. Peripheral neuropathy and arterial disease contribute to ulceration, impaired wound healing, and infection. *Staphylococcus aureus* is a common pathogen, though microbial profiles vary with geography, patient characteristics, and local resistance patterns. Effective management of DFIs relies on prompt diagnosis, guided by imaging and deep tissue cultures, to inform surgical and antimicrobial strategies. Surgical debridement and, in cases of osteomyelitis, excision of infected bone is critical for reducing recurrence and amputation risk. Antibiotic therapy should be tailored to culture results to optimize outcomes and curb resistance. Preventative measures, such as patient education, regular foot care, and specialized clinics, are essential in mitigating DFI risk. This systematic review consolidates findings from early reported studies, analyzing microbial profiles, antibiotic resistance trends, and clinical practice guidelines for diabetic foot management. It highlights the need for integrated approaches to improve patient outcomes and reduce the global burden of DFIs.

Keywords: Diabetes, Diabetic foot infections, Foot ulcers, Systematic review.

 $\textbf{Received:}\ 26\text{-}12\text{-}2024;\ \textbf{Accepted:}\ 20\text{-}02\text{-}2025;\ \textbf{Available Online}:$ 

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

#### 1. Introduction

Diabetes is a condition impacting millions globally, with its prevalence rising significantly over the past three decades. Diabetic neuropathy encompasses a diverse group of disorders affecting both the somatic and autonomic nervous systems. Among its clinical manifestations is diabetic foot (DF), characterized by structural or functional changes in the foot, including ulceration, infection, and gangrene.<sup>1</sup> These

issues often result from prolonged hyperglycemia and preexisting trauma, combined with varying degrees of peripheral vascular disease. Prevention and early intervention are key to avoid the development of DF. Consistently checking blood sugar levels, maintaining proper foot hygiene, and using suitable footwear are crucial for lowering the risk of diabetic foot (DF). People with diabetes should collaborate closely with their healthcare teams to prevent and address complications related to DF. Even without noticeable

\*Corresponding author: J Bindhu Email: bindhuraviedu0412@gmail.com

<sup>&</sup>lt;sup>1</sup>Dept. of Biotechnology, Sri Shakthi Institute of Engineering and Technology, Coimbatore, Tamil Nadu, India

<sup>&</sup>lt;sup>2</sup>Dept. of General Medicine, Sree Balaji Medical College Hospital, Chennai, Tamil Nadu, India

<sup>&</sup>lt;sup>3</sup>Dept. of General Surgery, Apollo Institute of Medical Sciences, Jubilee Hills, Hyderabad, Telangana, India

<sup>&</sup>lt;sup>4</sup> Dept. of Child Health Nursing, Nootan College of Nursing, Sankalchand Patel University, Visnagar, Gujarat, India

<sup>&</sup>lt;sup>5</sup>Dept. of Biomedical Sciences, Gulf Medical University, United Arab Emirates

Dept. of Biochemistry, MMK and SDM Mahila Mahavidyalaya Krishnamurthypuram, Mysuru, Karnataka, India

<sup>&</sup>lt;sup>7</sup>Center for Health Research, Northern Border University, Arar, Saudi Arabia

<sup>&</sup>lt;sup>8</sup>Dept. of Pharmaceutical Sciences, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, Tamil Nadu, India

<sup>&</sup>lt;sup>9</sup>Dept. of Pharmaceutical Biotechnology, Surya College of Pharmacy, Vikiravandi, Villupur, Tamil Nadu, India

symptoms, DF can lead to severe issues such as foot ulcers, Charcot osteoarthropathy, and, in extreme cases, amputation.<sup>2</sup> Diabetic foot infections (DFIs) represent a challenging and severe complication of diabetes mellitus, placing significant strain on healthcare systems worldwide. These infections, typically stemming from diabetes-related neuropathy and vascular issues, can result in serious consequences, including tissue destruction, amputations, prolonged hospitalizations, and increased risk of death.'3 Early detection and treatment of DFIs are crucial in preventing these consequences. Patients with diabetes should be educated on the importance of daily foot inspections, proper foot care, and seeking medical attention at the first sign of infection. Healthcare providers should be diligent in conducting thorough foot exams and promptly treating any wounds or infections that may arise.

A thorough knowledge of the microbiological characteristics and antibiotic resistance patterns of pathogens responsible for diabetic foot infections (DFIs) is crucial for successful treatment and better patient outcomes. DFIs involve a wide variety of microorganisms, with Staphylococcus aureus often recognized as a primary pathogen in numerous studies.<sup>4</sup> The composition of microbes differs greatly based on geographical region, individual patient factors, and the prevalence of antimicrobial resistance in the area. Therefore, healthcare providers must conduct thorough assessments and obtain appropriate cultures to diagnose and treat DFIs accurately. Prompt and effective treatment with antibiotics tailored to the specific pathogens present is essential to prevent the spread of infection and avoid serious complications such as cellulitis or osteomyelitis.<sup>5</sup> This knowledge helps healthcare providers choose the most appropriate antibiotic therapy to target the specific pathogens causing the infection. In addition, proper wound care and management are essential in preventing the spread of infection and promoting healing. In severe cases, surgical intervention may be necessary to remove infected tissue and promote healing. A multidisciplinary approach involving healthcare professionals, patients, and caregivers is essential to effectively manage DFIs and prevent long-term consequences in individuals with diabetes. By implementing preventative measures and staying vigilant in monitoring for signs of infection, patients with diabetes can significantly decrease their risk of serious complications and improve their overall quality of life. The onset of diabetic foot infections (DFIs) is closely linked to the microvascular and neuropathic complications associated with diabetes. Peripheral neuropathy, marked by sensory impairments and motor dysfunction, contributes to an increased risk of foot deformities, abnormal biomechanics, and pressure-related injuries or ulcers. The presence of peripheral arterial disease adds complexity by reducing blood flow, hindering wound healing, and fostering conditions favorable for infection. Preventative measures such as daily foot washing, moisturizing, thorough inspections, appropriate footwear, and maintaining good hygiene can help minimize the risk of

DFIs and associated complications. Additionally, managing blood glucose levels through proper medication, diet, and physical activity plays a crucial role in preventing DFIs and promoting foot health in individuals with diabetes. Healthcare providers often rely on advanced imaging modalities like magnetic resonance imaging (MRI) and computed tomography (CT), along with deep tissue cultures, to inform and optimize treatment strategies. Timely and accurate diagnoses is essential for initiating effective treatment, preventing complications, and lowering the risk of limb amputation or systemic infection. Surgical debridement plays a crucial role in addressing deep or severe infections by removing necrotic tissue and ensuring proper source control.

For osteomyelitis, removing the infected bone is often a definitive treatment that greatly reduces the chances of recurrence and the need for amputation. Tailored antimicrobial therapy, informed by culture and sensitivity testing, is essential for improving treatment success and minimizing antibiotic resistance. Implementing preventive measures is vital for lowering the incidence and severity of diabetic foot infections (DFIs).8 This involves patient education, encouraging routine foot checks, and facilitating prompt medical interventions. Recognizing high-risk individuals and launching focused strategies, like dedicated diabetic foot care clinics and structured treatment plans, can significantly reduce the occurrence of DFIs and related complications. Emerging research highlights the critical need to thoroughly examine the microbial profiles linked to DFIs and their patterns of antibiotic resistance. Numerous studies, including this systematic review, have explored the complex interplay between DFIs and antimicrobial resistance. This study aims to systematically review the evaluation and treatment strategies recommended in clinical practice guidelines for managing diabetic foot and related complications. This review consolidates data from relevant articles from PubMed and other reputable databases. Its goal is to provide an integrated overview of the microbial profiles in DFIs and emerging patterns in antibiotic resistance while also evaluating clinical practice guidelines addressing diabetic foot care and associated infections.

#### 2. Materials and Methods

## 2.1. Search strategy

The search and selection process was independently conducted by two blinded reviewers, with conflicts resolved by a third. Searches covered multiple databases, including PubMed, EMBASE, and Cochrane sources, for Englishlanguage studies published between 2017 and 2023. The search strategy was collaboratively developed using MeSH terms like "Diabetic Foot" and "Drug Resistance, Microbial." The query used was ("Diabetic Foot" [Mesh]) AND "Drug Resistance, Microbial" [Mesh]. The snowball method was also applied by reviewing reference lists of selected articles.

#### 2.2. Data extraction

The researchers collected and verified the relevant data, meticulously recording key details in a blank Microsoft Excel sheet. These details included the year of publication, authorship, geographic region, patient age range, total number of patients, predominant pathogens, resistance patterns of Gram-positive and Gram-negative bacteria, and the primary focus of each study. Data extraction from all eligible controlled studies was performed by one researcher and organized into an evidence table. This table summarized the population and study characteristics, intervention and control information, and the primary and secondary outcomes. A second researcher reviewed the extracted data to ensure accuracy and clarity. Lastly, the evidence tables were collaboratively reviewed and discussed by all authors.

#### 2.3. Inclusion and exclusion criteria

We included studies focusing on patients diagnosed with diabetic foot that addressed at least one predefined intervention and reported relevant outcomes. Excluded studies involved healthy individuals, those with non-diabetic conditions, or diabetic patients either without risk of foot ulcers or with active ulcers unless the latter reported on ulcer recurrence post-healing. Systematic reviews were excluded, but their references were checked to validate search results. Eligible studies addressed the prevention, assessment, diagnosis, and management of diabetic foot, compared clinical practice guidelines with strong internal validity, and

evaluated the quality of evidence and strength of recommendations.

## 2.4. Quality assessment

Two researchers, who were blinded to each other's assessments, evaluated the quality of the selected clinical practice guidelines (CPGs) using the Appraisal of Guidelines for Research and Evaluation (AGREE II) tool. This tool includes 23 items grouped into six domains, each assessing a specific aspect of guideline quality, as well as two global evaluation items to assess the overall guideline quality and recommendation status. Domain scores were calculated by summing the individual item scores and converting them into a percentage of the maximum possible score for that domain. The overall quality of the guidelines was rated on a scale from 1 (lowest) to 7 (highest), with guidelines scoring above 4 categorized as "quality CPGs." Following the AGREE II evaluation, the final guidelines were chosen, and the results were synthesized. The quality of the studies included was assessed using the JBI Critical Appraisal Tool for Analytical Cross-Sectional Studies, with all 10 studies meeting the criteria of at least five "YES" responses, qualifying them for inclusion in the systematic review synthesis.

#### 3. Discussion

After searching the databases, we identified 10 articles on diabetic foot infection and antibiotic resistance patterns in the systematic review conducted between 2017 and 2023. The reasons for excluding certain articles were as follows:




Figure 1: Flow chart

Table 1: Demographic distribution of patients by region, age range, and gender

Study	Region	Age/Range	Gender	Total patients
Emaneini	The study was conducted	The mean age of the patients	83 males and 32	115 patients were
$2022^{9}$	in Iran	was 59.3	females.	included in the study.
Jessica	The study was conducted	The participants in the study	The control group	A total of 31 patients
$2017^{10}$	in the Maule Region of	were between 18 and 80	consisted of 5 men and 3	were eligible for the
	Chile, specifically at the	years of age, focusing on	women.	study, with 20 in the
	Regional Hospital of	individuals with type 2	The Propolis group	propolis group and 11
	Talca.	diabetes.	consisted of 16 men and	in the control group.
			4 women.	
Qingfeng	The study was conducted	The mean age of the patients	67 men and 34 women.	101 patients were
$2022^{11}$	in China, specifically at	was $60.86 \pm 11.08$ years for		included in the study.
	the First Affiliated	type 2 diabetes patients,		
	Hospital of Chongqing	with 49 (50.0%) of these		
	Medical University.	patients being over 60 years old. For the 3 patients with		
		type 1 diabetes, the mean		
		age was $42.67 \pm 17.50$ years		
Nese	The study was conducted	Mean age: 59.90 years	193 males,	284 patients with
$2021^{12}$	across five centers in	Age range: 30 to 90 years		diabetic foot infections
	Turkey.	<b>8 8 9</b>		(DFI).
Vickie	The study was conducted	Mean Age for Group 1: 52.6	NR	12 patients with
$2012^{13}$	in the USA.	years $(SD = 3.8)$		diabetic
		Mean Age for Group 2: 64.8		foot ulcers(DFU)
		years $(SD = 8.7)$		
		Mean Age for Group 3: 50.8		
		years (SD = 8.5)		
Hikmat	The study focuses on	The study included patients	Groups: Group A:	The total number of
$2022^{14}$	Indonesia, specifically at Hasan Sadikin General	with diabetes mellitus aged over 18 years.	Gram (-):18 Females Gram (+):3 Females	patients in the study was 45
	Hospital in Bandung.	over 18 years.	mixed gram (-) and	was 45
	Hospital in Bandung.		gram (+):1 Female	
			Group B: Gram (-):16	
			Males Gram (+):5	
			Males	
			Mixed gram (-) and	
			gram (+): 2 Males	
Muhamm	The study was conducted	The mean age of the patients	134 (66.7%) male	201 patients
ad 2021 <sup>15</sup>	in Mayo Hospital,	was $53.05 \pm 10.70$ years		
<u> </u>	Lahore, Pakistan	m o i	710	210
Igor	The study was conducted	The average age of the	NR	210 patients with
$2021^{16}$	in Ukraine.	patients was 56.8 ± 2.5		sepsis due to
		years.		complicated diabetic
Rajasekar	The study was conducted	The mean age of the patients	Male patients were	foot syndrome.  The total number of
2019 <sup>17</sup>	in India.	was $53.04 \pm 12.12$ years	Male patients were predominant (34, 68%)	patients in the study
2019	m maia.	was 33.07 ± 12.12 years	Female patients (16,	was 50.
			32%).	
Yu-Yao	The study was conducted	The average age of patients	Limb preserved	The total number of
$2021^{18}$	at Chang Gung	with limb preservation was	60.2% males	patients analyzed in the
	Memorial Hospital,	62.9 years (± 14.0).	Poor outcome	study was 558
	located in Taiwan.	The average age of patients	65.0% males	,
	iocatcu iii Taiwaii.	The average age of patients		
	located in Taiwan.	with poor outcomes was 63.5 years (± 12.1)		

NR: Not reported

**Table 2:** Prevalence of pathogens in foot evaluations and screening outcomes

Study	Most prevalent pathogens	Foot evaluation	Screening
Emaneini	Staphylococcus spp., Escherichia coli,	Assessment of foot ulcers,	Regular checks for foot
20229	Klebsiella spp.	infections, and overall foot health	complications in diabetic
		in diabetic patients, including	patients, focusing on
		examination for neuropathy and	identifying early signs of
		peripheral arterial disease.	ulcers, infections, and other
			foot-related issues.
Jessica	The study provides a supplementary	A comprehensive assessment of	The process of identifying
$2017^{10}$	table for determining microorganisms	the foot's condition, including	individuals at risk for foot
	in diabetic foot wounds, but specific	inspection for ulcers, deformities,	complications, particularly
	and most prevalent pathogens are not listed.	and signs of infection, and evaluation of blood flow and nerve	in diabetic patients, through
	listed.	function.	regular examinations and assessments.
Qingfeng	Staphylococcus aureus (most	The study involved a retrospective	NR
2022 <sup>11</sup>	common)	evaluation of patients diagnosed	TVIC
2022	Enterococcus faecalis	with diabetic foot ulcers and	
	Streptococcus agalactiae	necrotizing fasciitis, following the	
	Gram-negative bacteria such as	diagnostic criteria set by the	
	Pseudomonas aeruginosa, Klebsiella	International Working Group on	
	pneumoniae, and Proteus mirabilis.	the Diabetic Foot (IWGDF).	
Nese	Staphylococcus aureus and	The study made a comprehensive	Regular foot screening for
202112	Escherichia coli	foot evaluation, including	diabetic patients to detect
	Other notable pathogens included	assessing wound depth, infection	potential issues like
	Klebsiella spp. and various Gram-	presence, and underlying	infection, ulceration, or
	negative and Gram-positive bacteria.	complications like neuropathy or	abnormalities early and
*** 1 .		vascular insufficiency.	manage them effectively.
Vickie 2012 <sup>13</sup>	Staphylococcus aureus, Pseudomonas	The study reported managing and	Screening involves testing
201213	aeruginosa, Escherichia coli, Streptococcus species, and fungal	treating diabetic sensorimotor polyneuropathy, emphasizing	individuals for specific diseases or conditions to
	pathogens like Candida can cause	standardized clinical assessments,	identify those at risk or
	wound infections, leading to severe	early detection of issues, and	needing further evaluation.
	complications and affecting wound	therapeutic footwear use to prevent	needing further evaluation.
	healing.	complications.	
Hikmat	The pathogens identified included	Foot evaluation included assessing	The study stressed regular
202214	Klebsiella pneumoniae, Acinetobacter	ulcer size, depth, presence of	-
	baumannii, Escherichia coli,	infection, and vascular status to	the early detection of
	Pseudomonas aeruginosa,	determine appropriate treatment	diabetic foot complications
	Staphylococcus aureus, and	for diabetic foot infections	and for preventing severe
	Enterococcus faecalis		outcomes
Muhammad	Bacterial Isolates: 389 total	Most Common Site of DFUs:	Deep-seated tissue samples
202115	- Gram-negative organisms: 238	- Forefoot: 129 (64.2%)	from the ulcer bed were
	(61.11%)	- Hindfoot: 49 (24.4%)	tested for culture and
	- Gram-positive organisms: 151 (38.89%)	- Midfoot: 23 (11.4%) DFU Grades:	sensitivity.
	- Common Pathogens: <i>Staphylococcus</i>	- Grade 3: 104 (51.7%)	
	aureus, $\beta$ -haemolytic streptococci,	- Grade 1: 62 (30.8%)	
	and gram-negative bacteria.	(20.0,0)	
Igor 2021 <sup>16</sup>	Staphylococcus aureus, Enterococcus	Assessed infection severity and	Involved in microbiological
	faecalis, Pseudomonas aeruginosa,	complications in patients with	studies of blood and wound
	Staphylococcus epidermidis,	diabetic foot syndrome.	discharge to identify
		1	
	Escherichia coli, Acinetobacter		pathogens.

Rajasekar	The study identified pathogens,	Foot evaluation in diabetic patients	Regular assessments to
2019 <sup>17</sup>	including Staphylococcus aureus,	assessed for ulcers, infections,	identify diabetic foot
	Bacillus subtilis, Enterococcus	neuropathy, and vascular issues to	complications early,
	faecalis, and Gram-negative bacteria	prevent complications and promote	preventing severe outcomes.
	in diabetic foot infections.	healing.	
Yu-Yao	Common pathogens include	Assessing foot condition to	Regular checks for foot
202118	Streptococcus spp., Staphylococcus	identify complications and prevent	problems to ensure early
	aureus, E. coli, Proteus spp.,	further issues in diabetic patients	detection and management
	Pseudomonas spp.,		of diabetic foot
	Peptostreptococcus spp., and		complications
	Bacteroides spp.		

NR: Not reported

## 3.1. Screening and evaluation

A comprehensive evaluation of diabetic foot health has emphasized the assessment of ulcers, infections, and complications such as neuropathy and vascular insufficiency. Several studies have highlighted the diagnostic criteria established by the International Working Group on the Diabetic Foot (IWGDF) for identifying and managing diabetic foot ulcers (DFUs). The research noted the prevalence of DFUs, with the forefoot being the most common site (64.2%) and Grade 3 ulcers (51.7%) representing the most severe cases. Other studies have focused on early detection, standardized assessments, and therapeutic interventions, emphasizing the critical role of evaluating infection severity and vascular health to promote healing and prevent complications. The importance of a multidisciplinary approach to managing DFUs was also stressed, involving podiatrists, wound care specialists, infectious disease experts, and vascular surgeons. Additionally, the significance of patient education on foot care and self-management strategies to prevent recurrent ulcers was underscored. Overall, the findings highlight the complex nature of DFUs and the necessity for comprehensive assessment and treatment strategies to improve outcomes and minimize the risk of amputation in diabetic patients.(Table 2)

#### 3.2. Most prevalent pathogens

The most common pathogens identified in diabetic foot infections (DFI) include Staphylococcus aureus, Escherichia coli, Klebsiella spp., and both Gram-negative and Grambacteria. Research has confirmed Staphylococcus spp., E. coli, and Klebsiella spp. are frequently implicated as causative organisms. Additionally, studies have reported the presence of Staphylococcus aureus, Enterococcus faecalis, and Streptococcus agalactiae, emphasizing the importance of proper wound care and targeted antibiotic therapy in managing these infections. Understanding the specific pathogens involved allows healthcare providers to tailor treatments to effectively target the bacteria causing the infection. Other research highlights Pseudomonas aeruginosa, Klebsiella pneumoniae, and Proteus mirabilis as significant contributors, while

Staphylococcus aureus, Pseudomonas aeruginosa, and Candida fungi have also been identified as key pathogens. These findings underscore the diverse range of microorganisms that may contribute to diabetic foot infections, stressing the need for a targeted treatment approach. By identifying the bacteria or fungi responsible, healthcare providers can prescribe the most effective antibiotics or antifungal medications, leading to improved patient outcomes and reduced risk of complications. Gramnegative bacteria like Acinetobacter baumannii and Grampositive bacteria such as Enterococcus faecalis and Staphylococcus epidermidis have been frequently observed. Additional studies have noted the presence of β-haemolytic Bacillus subtilis, Proteus spp., streptococci, Peptostreptococcus spp., further highlighting the diversity of pathogens in DFIs. These findings emphasize the critical role of precise pathogen identification in optimizing treatment regimens for diabetic foot infections.

# 3.3. Pathogenesis and diagnosis

The onset of diabetic foot infections (DFIs) is driven by several factors, primarily linked to diabetes-related complications like peripheral neuropathy, peripheral arterial disease, and impaired immune function. Peripheral neuropathy leads to a loss of sensation and motor control, raising the risk of undetected injuries and skin damage. Additionally, high blood glucose levels in diabetes promote bacterial growth and impair immune responses, creating favorable conditions for infections.<sup>20</sup> Collectively, these factors greatly increase the likelihood of diabetic foot infections (DFIs) in individuals with diabetes. Diagnosing DFIs involves a thorough clinical assessment, looking for symptoms such as redness, warmth, swelling, and discharge. Imaging tools, including X-rays and more advanced methods, are used to evaluate soft tissue damage and possible osteomyelitis. Laboratory tests, like elevated inflammatory markers (e.g., C-reactive protein and erythrocyte sedimentation rate), help confirm the presence of infection.<sup>21</sup> Molecular diagnostic techniques enable the identification of various bacteria, including those that are challenging to culture and anaerobic, assisting in the selection of targeted antimicrobial therapies. Advanced imaging methods, such as

contrast-enhanced MRI and PET-CT scans, enhance the detection of soft tissue infections, osteomyelitis, and deep abscesses. These technologies allow clinicians to tailor treatment strategies according to the specific infection characteristics, resulting in more effective interventions and improved patient outcomes. The use of these advanced diagnostic tools enables healthcare providers to make earlier and more accurate diagnoses, leading to more precise and individualized treatments for complex diabetic foot infections (DFIs).

## 3.4. Risk factors for DFIs

The increased likelihood of antibiotic resistance in diabetic foot infections (DFIs) is associated with factors like higher BMI, elevated HbA1c, higher fasting blood glucose, and the size and progression of the ulcer. These factors highlight the complex interaction between the host's characteristics and the microbes' resistance to antibiotics. Excess body weight promotes chronic inflammation and a weakened immune response, fostering conditions that support microbial growth and resistance. Additionally, the surplus adipose tissue in individuals with a high BMI can provide a favorable environment for pathogens, contributing to prolonged infections and decreased antibiotic efficacy.<sup>23</sup> High blood

glucose levels encourage bacterial proliferation and biofilm development, which in turn contribute to increased resistance. The extent and persistence of the ulcer, as reflected by its size and progression, are often linked to the presence of various microbial communities, including antibiotic-resistant strains. Host-related factors, such as immune function, coexisting health conditions, and anatomical characteristics, also play a role in shaping the microbial makeup of polymicrobial infections and can impact the virulence of the involved microorganisms.<sup>24</sup> Recent research on diabetic foot infections (DFIs) has highlighted several risk factors, including previous hospitalizations, ulcer size, surgical interventions, and increased C-reactive protein levels. Hospital-acquired infections, often linked to poor hygiene and insufficient infection control measures, play a significant role in the issue. Notably, larger ulcers are considered a key prognostic indicator.<sup>25</sup> Common pathogens in severe infections include Staphylococcus aureus, Enterococcus, facultative gram-negative bacilli, and group B streptococci, with hospital ward conditions often exacerbating these infections.<sup>26</sup> Research indicates that, despite these challenges, treating diabetic foot infections (DFIs) does not contribute to an increase in antibiotic resistance, and recurrent infections do not necessarily lead to higher antimicrobial resistance in future episodes.

**Table 3:** Debridement and treatment strategies

Study	Debridement	Dressings	Treatment strategies	Neuropathic pain
Emaneini	The study emphasizes the	Protective coverings are	Comprehensive	The study found that
20229	significance of	applied to wounds to	approaches combining	neuropathic pain is
	debridement in managing	maintain a moist	medication, lifestyle	linked to diabetic
	diabetic foot infections,	environment, absorb	changes, and wound care	foot ulcers,
	involving wound	exudate, and prevent	to manage diabetic foot	classified as
	cleaning, tissue removal,	infection, aiding in the	complications effectively	Neuropathic (N) by
	microbiological analysis,	healing process of diabetic	enhanced patient	the Meggitt-Wagner
	and patient healing to	foot ulcers.	treatment outcomes.	classification
	enhance infection control.			system. This
				classification helps
				understand foot
				ulcer causes and
				influences treatment
				strategies and
				patient outcomes.
Jessica		Protective materials were	The study compared	A study by Jessica
2017 <sup>10</sup>	NR	applied to wounds to	propolis treatment for	Zuñiga-Hernandez
		protect them, absorb	diabetic foot wounds to	and colleagues
		exudate, and promote a	standard care,	found that propolis
		moist healing environment.	emphasizing the need for	significantly
		The choice of dressing	consistent	reduced wound area
		varied based on the	pharmacological	in diabetic foot
		wound's characteristics.	treatment and specialized	ulcers, highlighting
			care protocols.	the importance of
				addressing
				neuropathic pain and
				inflammation in
				wound management,

Qingfeng 2022 <sup>11</sup>	The study highlights that surgical intervention is crucial for treating necrotizing fasciitis, often involving debridement to remove necrotic tissue and control the infection.	NR	The study advocates for prompt, aggressive surgical treatment and appropriate antibiotic therapy for managing DNF, emphasizing the importance of understanding microbial distribution for effective	especially in patients with type 1 or 2 diabetes.  NR
Nese 2021 <sup>12</sup>	Debridement is a crucial procedure in managing DFI, involving removing necrotic tissue and foreign material to promote healing and reduce infection risk.	NR	treatment.  Diabetic foot infections require a multidisciplinary approach, including antibiotic therapy, regular foot evaluations, therapeutic footwear, wound care, and surgical interventions like debridement when necessary.	A study on 284 diabetic foot infections revealed rheopathic pain, osteomyelitis, and the need for broadspectrum antibiotic regimens and deescalation despite limitations like small sample size and smoking status exclusion.
Vickie 2012 <sup>13</sup>	Regular de Abridgment and advanced treatment modalities like NCLF-US can significantly improve wound healing and reduce inflammation in diabetic foot ulcers, highlighting the importance of regular debridement in patient outcomes.	This study found that non-contact low-frequency ultrasound treatment reduced wound area by 86% over five weeks, potentially enhancing tissue regeneration by modulating inflammatory responses.	Treatment strategies implemented are planned approaches to manage diseases, incorporating medications, therapies, lifestyle changes, and patient education for optimal health outcomes.	NCLF-US can effectively treat diabetic foot ulcers by reducing proinflammatory cytokines, reducing wound area by 86%, and promoting healing.
Hikmat 2022 <sup>14</sup>	This study suggests debridement is crucial for managing diabetic foot infections, which have a high prevalence of Gramnegative bacteria.	This study emphasizes the importance of proper wound care, including cleaning ulcers with sterile saline and using aseptic techniques. Advanced wound care products, such as hydrocolloids, alginates, and antimicrobial dressings, are typically used.	Effective treatment strategies for diabetic foot infections included timely antibiotic administration, wound care, and addressing underlying conditions.	NR

			T	
Muhammad	The study emphasizes the	Dressings protect wounds,	Antimicrobial	Neuropathy
202115	significance of	absorb exudate, and	Susceptibility:	significantly affects
	debridement in managing	promote healing.	Determined according to	89.1% of diabetic
	diabetic foot ulcers,	Hydrocolloid, foam,	Clinical and Laboratory	foot ulcers,
	which involves removing	alginate, transparent film,	Standards Institute	necessitating
	slough and necrotic	and antimicrobial dressings	guidelines.	targeted treatment
	tissue, washing	were used.		strategies to
	thoroughly, and sending		Empirical Treatment:	alleviate the
	samples for culture and		Early identification of	underlying pain in
	sensitivity testing.		infections for timely	affected individuals.
	sensitivity testing.		initiation of treatment.	unceted marviduals.
Igor 2021 <sup>16</sup>	A study of 210 diabetic	Protective coverings were	Comprehensive	The study revealed
1g01 2021	_ ·	Protective coverings were	-	•
	foot syndrome patients	applied to wounds to	approaches combining	diabetic neuropathy,
	underwent surgical	maintain moisture, prevent	medication, lifestyle	a common
	intervention to address	infection, and facilitate	changes, and wound care	complication of
	purulent-necrotic lesions,	healing in diabetic foot	to manage diabetic foot	diabetes, can cause
	aiming to improve	injuries.	complications.	neuropathic pain,
	outcomes and reduce			exacerbated by foot
	mortality rates.			lesions, affecting 86
				patients with
				diabetic foot
				syndrome.
Rajasekar	This study reported	Specialized coverings were	Comprehensive	The study highlights
$2019^{17}$	multiantibiotic-resistant	used for wounds to	approaches included	chronic pain in
	bacteria in wound swabs	promote healing and	medication, wound care,	diabetic foot ulcers
	from 50 patients,	protect against infection in	and lifestyle	due to neuropathy,
	emphasizing the need for	diabetic foot ulcers.	modifications to manage	high pressures,
	new strategies to clean		diabetic foot	vascular
	and disinfect ulcers.		complications effectively.	insufficiency, and
				impaired neutrophil
				function, causing
				infection persistence
				and prolonged
				treatment.
Yu-Yao	The study emphasizes the		Comprehensive	
2021 <sup>18</sup>	significance of	NR	approaches to managing	NR
	debridement in ulcer		diabetic foot infections	
	management, removing		included wound care,	
	necrotic tissue for		antibiotics, and surgical	
	accurate diagnosis and		interventions.	
	treatment, and collecting		mor vontions.	
	bacterial and fungal			
	cultures for broad-			
	1			
NR: Not report	therapy.			

NR: Not reported

 Table 4: Use of antibiotics and adjuvant treatments

Study	Most Effective Against Microbial		Therapeutic Footwear		Antibiotherapy	Adjuvant Treatments
Emaneini	Imipenem,	piperacillin-	Specialized	shoes	The study highlighted	Additional therapies,
20229	tazobactam, amil	kacin was	designed to	provide	the need for	such as growth
	used.		support,	reduce	personalized	factors, are used
			pressure,	and	antibiotic therapy for	alongside primary

Jessica 2017 <sup>10</sup>	NR	accommodate foot deformities, helping prevent ulcers and promote healing in diabetic patients were provided.  Specialized shoes designed to provide	diabetic foot infections, emphasizing the ineffectiveness of standard treatments like clindamycin and ciprofloxacin due to high resistance rates.	treatments to enhance healing, reduce infection risk, and improve outcomes in diabetic foot care.  Additional therapies, such as topical agents
		support, reduce pressure, and prevent foot injuries in individuals with diabetes or other foot conditions were provided		like propolis or other natural products, are used alongside primary treatments to enhance healing.
Qingfeng 2022 <sup>11</sup>	Effective antibiotics include linezolid, vancomycin, tigecycline, and daptomycin for Gram-positive bacteria and various options for Gram-negative pathogens.	Therapeutic footwear is designed to provide support, reduce pressure, and prevent ulcers in patients with diabetes or foot deformities.	The study emphasizes the need for appropriate antibiotic therapy for diabetic foot infections involving necrotizing fasciitis, recommending levofloxacin, moxifloxacin, vancomycin, teicoplanin, tigecycline, linezolid, carbapenems, and amikacin for Gramnegative bacteria.	NR
Nese 2021 <sup>12</sup>	The most common initial antimicrobial regimens include beta-lactam/beta-lactamase inhibitor combinations, fluoroquinolones, and daptomycin. Vancomycin was identified as an independent predictor of reinfection/death when treatment was inappropriate.	offer adequate foot support and protection, thereby reducing the risk of ulcers and injuries.	The study found that beta-lactam/beta-lactam/beta-lactamase inhibitor combinations are the most commonly used initial regimens for treating DFI based on clinical findings and local epidemiological data.	like gabapentin and duloxetine, which can alleviate pain and enhance patient comfort.
Vickie 2012 <sup>13</sup>	Effective antibiotics include amoxicillin, ceftriaxone, azithromycin, ciprofloxacin, doxycycline, vancomycin, clindamycin, gentamicin, and linezolid for various infections.	Therapeutic footwear supports and protects feet, reducing pressure and preventing ulcers, especially for individuals with diabetes or foot deformities.	NR	The study found that non-contact low-frequency ultrasound (NCLF-US) effectively treated diabetic foot ulcers, reducing wound area and improving tissue regeneration.
Hikmat 2022 <sup>14</sup>	Antibiotics effective against microbial infections included carbapenems, amikacin, tigecycline, vancomycin,	Therapeutic footwear was provided to support and protect feet, reducing the risk	The study highlights antibiotic therapy challenges due to local bacterial	Adjuvant treatments, such as analgesics and topical agents, were used to enhance

	ampicillin-sulbactam, and cephalosporins.	of ulcers and injuries in people with diabetes.	susceptibility. Common antibiotics for Gram-negative bacteria are poor, while effective options include carbapenems, gentamicin, tigecycline, and vancomycin. The authors call for a re- evaluation of empirical antibiotic choices.	the effectiveness of primary therapies for diabetic foot infections.
Muhammad 2021 <sup>15</sup>	Methicillin-resistant  Staphylococcus aureus: Found in 62 (64.58%) isolates.	Therapeutic footwear provides support and protection for diabetic patients, featuring extra depth, cushioning, stability, and custom orthotics to prevent ulcers.	The study outlines antibiotic therapy guidelines for diabetic foot infections based on severity. Grade I infections require no antibiotics, while Grade II require narrow-spectrum oral antibiotics. Grade III infections require double intravenous therapy with cephalosporins and oral agents.	Adjuvant treatments enhanced healing through offloading, physical therapy, nutritional support, and advanced therapies like negative pressure wound therapy.
Igor 2021 <sup>16</sup>	Daptomycin, linezolid, teicoplanin, vancomycin, tigecycline, aminoglycosides, fluoroquinolones, and macrolides.	Specialized shoes are designed to support, reduce pressure, accommodate foot deformities, and prevent injuries in individuals with diabetes or foot conditions.	Studying timely antibiotic therapy reduces mortality and complications, particularly for Grampositive bacteria like <i>Staphylococcus</i> aureus, emphasizing the need for tailored approaches.	Additional therapies, such as physical therapy or medications, are used alongside primary treatments to enhance effectiveness.
Rajasekar 2019 <sup>17</sup>	Antibiotics tested included amikacin, amoxicillin, cefotaxime, ciprofloxacin, gentamycin, penicillin, tetracycline, and vancomycin against microbial infections in DFUs.	Specialized shoes are designed to reduce pressure and support diabetic patients, preventing ulcers.	This study revealed that Gram-negative bacteria exhibit 100% resistance to amoxicillin and cotrimoxazole and varying resistance rates to erythromycin, penicillin, and vancomycin.	Additional therapies, such as physical therapy and alternative medicine, are used alongside primary treatments to enhance healing outcomes.
Yu-Yao 2021 <sup>18</sup>	Broad-spectrum antibiotics included third-generation cephalosporins, extended-spectrum penicillins, fluoroquinolones, carbapenems, metronidazole,	Specialized shoes designed to provide support and prevent injuries in patients with diabetic foot issues	The study examined diabetic foot infections in patients and utilized broadspectrum antibiotic therapy, including cephalosporins,	The study suggested adjuvant treatments for limb-threatening diabetic foot infections, including adjunct angiography,

and glycopeptides for MRSA	penicillins,	wound cultures, and
treatment.	fluoroquinolones, and	surgical
	carbapenems, with	interventions, to
	additional MRSA	improve infection
	coverage based on	management and
	wound cultures.	patient outcomes.

Table 5: Challenges and recommendations in developing and adopting standard guidelines: limitations and strengths

Study	Challenges in developing and	Recommendations	Limitations and strengths
Emaneini	adopting Standard Guidelines  Creating and implementing	Implement tailored treatment	Study limitations include sample
20229	effective clinical guidelines is difficult due to varying patient needs, resistance to change, and resource limitations in healthcare settings.	plans, regular monitoring, and patient education to improve outcomes in diabetic foot care and management.	size; strengths include comprehensive data collection and insights into local bacterial resistance patterns.
Jessica 2017 <sup>10</sup>	The study highlights the growing issue of chronic wounds in healthcare systems, highlighting the need for improved therapies and understanding of their molecular and cellular environment.	Recommendations included best practices, patient education, research directions, and new therapy implementation.	Limitations of the study include small sample size, short duration, potential biases, and external variables, while strengths include robust design, comprehensive data collection, well-defined population, and clinical practice impact.
Qingfeng 2022 <sup>11</sup>	The study highlights the need for more research on the distribution and drug sensitivity of pathogenic bacteria in DNF patients, which hinders the creation of comprehensive treatment guidelines.	The study recommends using broad-spectrum antibiotics initially, considering the high risk of multi-drug resistant bacteria and the potential for amputation in DNF patients.	The study offers valuable insights into microbial distribution and drug sensitivity in DNF patients, potentially informing empirical treatment strategies due to its retrospective nature and single-center design.
Nese 2021 <sup>12</sup>	Challenges in healthcare include local practice variability, resource disparities, ongoing provider education, and antibiotic resistance's rapid emergence, complicating standardized treatment protocols.	Regular foot health screening, early antibiotic therapy, multidisciplinary care, and patient education on foot care and glycemic control are recommended for managing diabetic foot infections.	The study has limitations like small sample size and potential biases, but its strengths include its multicenter design and comprehensive assessment of factors influencing diabetic foot infection outcomes.
Vickie 2012 <sup>13</sup>	Challenges in developing and adopting guidelines include varying evidence quality, stakeholder consensus, resource limitations, and resistance to change among practitioners.	Treatment recommendations must be tailored to patient needs, regularly updated, and include multidisciplinary collaboration to enhance treatment effectiveness and adherence.	Strengths include robust methodology and clear outcomes; limitations involve small sample size, short duration, and potential biases in participant selection.
Hikmat 2022 <sup>14</sup>	Challenges include varying bacterial patterns, resistance issues, and the need for localized guidelines tailored to specific populations.	Recommendations emphasized the importance of individualized treatment plans based on local microbiological data and patient-specific factors.	Limitations include potential antibiotic resistance and variability in patient responses, while strengths involve comprehensive management approaches and multidisciplinary care.
Muhammad 2021 <sup>15</sup>	The geographic diversity of organisms and evolving local antibiotic resistance patterns emphasize the clinical	Emphasized for timely treatment to prevent amputations.	The study's single-center design limits generalizability but offers a comprehensive analysis of

	significance of regional data for effective treatment.		microbial patterns and antibiotic sensitivity in many patients.
Igor 2021 <sup>16</sup>	Barriers include variability in patient populations, resistance patterns, and resource limitations affecting implementation.	Evidence-based suggestions for managing diabetic foot conditions, emphasizing prevention, early intervention, and multidisciplinary care.	· I
Rajasekar 2019 <sup>17</sup>	Variability in patient populations, resistance patterns, and resource availability complicate standardization of care protocols.	Implementing evidence-based practices, regular screenings and patient education is recommended to improve outcomes in diabetic foot care.	Limitations included variability in studies; strengths involve comprehensive data supporting effective interventions for diabetic foot management.
Yu-Yao 2021 <sup>18</sup>	Difficulties in creating and implementing effective protocols for diabetic foot care due to variability in patient needs	Evidence-based suggestions for managing diabetic foot infections to improve patient outcomes and reduce complications	gram-negative bacteria and

### 3.5. Treatment strategies

The reviewed studies highlight various treatment strategies for managing diabetic foot complications and infections. Comprehensive approaches that integrate medication, lifestyle changes, and wound care were emphasized. The importance of timely surgical intervention and understanding microbial distribution was also stressed. Multidisciplinary methods incorporating antibiotics, therapeutic footwear, and wound care were recommended. The effectiveness of propolis alongside standard care was noted, and planned, patient-centered strategies combining education and therapy were identified as essential for improving outcomes. To continue, innovative techniques such as the use of bioengineered skin substitutes and advanced dressings were shown to promote wound healing effectively. The role of negative pressure wound therapy in managing complex cases was highlighted, as was the potential of growth factors and stem cell therapies in enhancing tissue regeneration. Telemedicine and digital tools for monitoring diabetic foot ulcers were also identified as promising approaches to ensure consistent patient follow-up and early detection of complications. Additionally, the integration of psychosocial support into treatment plans was emphasized to address the mental health challenges often associated with chronic diabetic foot conditions.(Table 3)

# 3.6. Most effective antibiotics against microbial infection

Studies on effective antibiotics for microbial infections have highlighted various options based on the pathogen and clinical context. For Gram-positive bacteria, linezolid, vancomycin, tigecycline, and daptomycin are frequently recognized as effective. Broad-spectrum treatments often involve carbapenems, cephalosporins, fluoroquinolones, and beta-lactam/beta-lactamase inhibitor combinations. Specific

regimens, such as amikacin, imipenem, and piperacillintazobactam, have demonstrated efficacy in multiple cases. Additionally, newer antibiotics like teicoplanin and aminoglycosides have shown potential against resistant strains. Effective treatments for Methicillin-resistant \*Staphylococcus aureus\* (MRSA) often include glycopeptides and carbapenems. However, the rise of multidrug-resistant pathogens underscores the importance of antibiotic stewardship and thorough susceptibility testing. Notably, inappropriate use of vancomycin has been associated with higher risks of reinfection and mortality, highlighting the need for targeted therapies and meticulous monitoring to achieve optimal clinical patient outcomes.(Table 4)

## 4. Challenges in Developing and Adopting Guidelines

Developing and implementing standardized guidelines for diabetic foot infections (DFIs) presents numerous challenges, as highlighted by various studies. These challenges include significant variation in the clinical presentation and severity of DFIs, the absence of universally accepted diagnostic criteria, and difficulties in distinguishing infections from other common diabetic foot complications. The diverse nature of the diabetic population and the presence of multiple comorbidities further complicate the establishment of standardized protocols. Despite these obstacles, ongoing efforts focus on improving the management of DFIs through collaborative research and evidence-based strategies. Resistance to change, limited resources, and variability in patient needs have been identified as significant barriers. Additionally, there is a need for greater understanding of the chronic wound environment and more research on the distribution of pathogenic bacteria and drug sensitivity. Addressing these barriers is crucial for advancing treatment methods and enhancing outcomes for patients with DFIs. Overcoming resistance to change, securing adequate

resources, and improving knowledge of chronic wound dynamics can help healthcare providers develop more effective treatment strategies, ultimately improving care quality. Local practice variability, antibiotic resistance, and region-specific guidelines also pose challenges. Geographic diversity and resistance patterns must be considered in clinical practices to ensure effective management. Patient population variability further impacts the development of protocols, emphasizing the necessity of tailored approaches for successful implementation. These insights underscore the importance of addressing regional differences in practice, resistance trends, and patient demographics. Collaboration among researchers, clinicians, and policymakers is essential for creating comprehensive guidelines that address the complexities of managing DFIs across diverse regions and populations.(**Table 5**)

## 5. Recommendations

Studies have provided evidence-based recommendations for managing diabetic foot infections (DFIs), emphasizing prevention, early intervention, and multidisciplinary care. Researchers highlight the importance of tailored treatment plans, regular updates to guidelines, and patient education to address the complexities of chronic wound environments. A comprehensive approach to managing DFIs is widely regarded as essential for preserving limb function and quality of life in diabetic patients. By staying informed on the latest findings and guidelines, healthcare providers can deliver effective, individualized care. Experts advocate for timely intervention with broad-spectrum antibiotics to reduce the of multi-drug resistance and amputations. risks Individualized treatments based on local microbiological data and resistance patterns are also recommended. Regular screenings and collaboration among healthcare professionals from various disciplines are emphasized to address the challenges of managing DFIs effectively. Preventive measures and early management strategies are considered critical for improving patient outcomes. By implementing evidence-based practices, healthcare providers significantly enhance the quality of care for DFIs, reduce complications, and alleviate the burden on healthcare systems by preventing costly outcomes such as amputations.<sup>27</sup> This collaborative and informed approach underscores the importance of ongoing education and teamwork in improving the management of diabetic foot infections.

#### 6. Conclusion

Diabetic foot infections (DFIs) are complex clinical conditions requiring a multifaceted diagnosis, management, and prevention approach. Predominantly isolated Grampositive microbes in DFIs include Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Streptococcus agalactiae, and Staphylococcus epidermidis. At the same time, Gram-negative species often involve Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis,

and Pseudomonas aeruginosa. Risk factors contributing to antimicrobial resistance in DFIs include elevated BMI, HbA1c levels, blood glucose, ulcer characteristics, neuropathy, and vascular disease. A multidisciplinary team (MDT) approach is critical in DFI prevention and management, particularly involving podiatrists. Future research should prioritize understanding antibiotic resistance mechanisms, developing new agents, and advancing stewardship programs alongside collaborations and clinical address management trials limitations. recommendations include judicious antibiotic use, enhanced surveillance, and promoting interventions like debridement (highly evidence-backed and strongly recommended), regular foot evaluations, and therapeutic footwear (moderately supported and fairly recommended) to optimize outcomes despite variations in clinical guidelines.

# 7. Source of Funding

None.

#### 8. Conflict of Interest

Conflict of interest declared none.

#### References

- Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. *Clin Diabetes*. 2015;33(1):40– 8. doi: 10.2337/diaclin.33.1.40.
- Schmidt BM, Holmes CM. Updates on diabetic foot and Charcot osteopathic arthropathy. Curr Diab Rep. 2018;18(10):74. doi: 10.1007/s11892-018-1047-8.
- Costa RH, Cardoso NA, Procópio RJ, Navarro TP, Dardik A, de Loiola Cisneros L. Diabetic foot ulcer carries high amputation and mortality rates, particularly in the presence of advanced age, peripheral artery disease and anemia. *Diabetes Metab* Syndr. 2017;11(Suppl 2):S583–7. doi: 10.1016/j.dsx.2017.04.008.
- Shettigar K, Murali TS. Virulence factors and clonal diversity of Staphylococcus aureus in colonization and wound infection with emphasis on diabetic foot infection. Eur J Clin Microbiol Infect Dis. 2020;39(12):2235–46.
- Mandell JC, Khurana B, Smith JT, Czuczman GJ, Ghazikhanian V, Smith SE. Osteomyelitis of the lower extremity: pathophysiology, imaging, and classification, with an emphasis on diabetic foot infection. *Emerg Radiol*. 2018;25(2):175–88. doi: 10.1007/s10140-017-1564-9.
- Komarraju A, Chhabra A. Advanced cross-sectional radiologyultrasound, computed tomography and magnetic resonance imaging of the diabetic foot. The Foot in Diabetes. John Wiley & Sons Ltd. 2020 Apr 24:169–85. 10.1002/9781119445821.ch10
- Tom LK, Wright TJ, Horn DL, Bulger EM, Pham TN, Keys KA. A skin-sparing approach to the treatment of necrotizing soft-tissue infections: thinking reconstruction at initial debridement. *J Am Coll Surg.* 2016;222(5):e47–60. doi: 10.1016/j.jamcollsurg.2016.01.008.
- Hatipoglu M, Mutluoglu M, Turhan V, Uzun G, Lipsky BA, Sevim E et al. Causative pathogens and antibiotic resistance in diabetic foot infections: a prospective multi-center study. *J Diabetes Complications*. 2016;30(5):910–6.
- Taki E, Jabalameli F, MR MT, Feizabadi MM, Beigverdi R, Emaneini M. Microbial profile and antibiotic susceptibility pattern in diabetic patients with mild, moderate, and severe foot infections in Tehran. *Arch Razi Inst.* 2022;77(5):1925–33. doi: 10.22092/ARI.2022.359759.2476.
- Mujica V, Orrego R, Fuentealba R, Leiva E, Zúñiga-Hernández J. Propolis as an adjuvant in the healing of human diabetic foot

- wounds receiving care in the diagnostic and treatment centre from the regional hospital of Talca. *J Diabetes Res.* 2019;2019:2507578.
- Li X, Du Z, Tang Z, Wen Q, Cheng Q, Cui Y. Distribution and drug sensitivity of pathogenic bacteria in diabetic foot ulcer patients with necrotizing fasciitis at a diabetic foot center in China. *BMC Infect Dis*. 2022;22(1):396. doi: 10.1186/s12879-022-07382-7.
- Saltoglu N, Surme S, Ezirmik E, Kadanali A, Kurt AF, Sahin Ozdemir M et al. The effects of antimicrobial resistance and the compatibility of initial antibiotic treatment on clinical outcomes in patients with diabetic foot infection. *Int J Low Extrem Wounds*. 2023;22(2):283–90.
- Yao M, Hasturk H, Kantarci A, Gu G, Garcia-Lavin S, Fabbi M et al. A pilot study evaluating non-contact low-frequency ultrasound and underlying molecular mechanism on diabetic foot ulcers. *Int* Wound J. 2014;11(6):586–93. doi: 10.1111/iwj.12005.
- Permana H, Saboe A, Soetedjo NN, Kartika D, Alisjahbana B. Empirical antibiotic for diabetic foot infection in Indonesian tertiary hospital, is it time to rethink the options?. *Acta Medica Indonesiana*. 2022;54(2):247–54.
- Siddiqui MA, Naeem H, Ali MM, Randhawa FA, Nazir S, Farooqui F. Microbiological and antimicrobial pattern of diabetic foot ulcers (DFUs) at a tertiary care center in North East, Punjab. *J Pak Med Assoc.* 2021;71(6):1566–9. doi: 10.47391/JPMA.1180.
- Savon IL, Shapoval SD, Maksymova OO, Sofilkanych MM, Sheremet MI, Shidlovskyi OV et al. Alternative antibacterial therapy of methicillin-resistant Staphylococcus aureus in patients with diabetic foot and sepsis. *Rom J Diabetes Nutr Metab Dis*. 2021;28(1):11–7.
- Thanganadar Appapalam S, Muniyan A, Vasanthi Mohan K, Panchamoorthy R. A study on isolation, characterization, and exploration of multiantibiotic-resistant bacteria in the wound site of diabetic foot ulcer patients. *Int J Low Extrem Wounds*. 2021;20(1):6–14. doi: 10.1177/1534734619884430.
- Hung SY, Chiu CH, Huang CH, Lin CW, Yeh JT, Yang HM et al. Impact of wound microbiology on limb preservation in patients with diabetic foot infection. *J Diabetes Investig*. 2022;13(2):336– 43. doi: 10.1111/jdi.13649.
- 19. Xin H, Fu Y, Feng M, Wang S, Sui C, Gao Y et al. Altered intrinsic brain activity related to neurologic and motor dysfunction in

- diabetic peripheral neuropathy patients. *J Clin Endocrinol Metab*. 2023;108(4):802–11. doi: 10.1210/clinem/dgac651.
- Ohara-Nemoto Y, Nakasato M, Shimoyama Y, Baba TT, Kobayakawa T, Ono T et al. Degradation of incretins and modulation of blood glucose levels by periodontopathic bacterial dipeptidyl peptidase 4. *Infect Immun*. 2017;85(9):e00277–17. doi: 10.1128/IAI.00277-17.
- Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. 10.3389/fimmu.2018.00754
- Tuttolomondo A, Maida C, Pinto A. Diabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetes. World J Orthop. 2015;6(1):62–76. doi: 10.5312/wjo.v6.i1.62.
- Chiricozzi A, Raimondo A, Lembo S, Fausti F, Dini V, Costanzo A et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. *Expert Rev Clin Immunol*. 2016;12(12):1299–308.
- Laudisio A, Marinosci F, Fontana D, Gemma A, Zizzo A, Coppola A et al. The burden of comorbidity is associated with symptomatic polymicrobial urinary tract infection among institutionalized elderly. *Aging Clin Exp Res*. 2015;27(6):805–12. doi: 10.1007/s40520-015-0364-x.
- Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. *Asian Pacific J Trop Biomed*. 2017;7(5):478–82. 10.1016/j.apjtb.2017.01.019
- Huang L, Zhang R, Hu Y, Zhou H, Cao J, Lv H et al. Epidemiology and risk factors of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci infections in Zhejiang China from 2015 to 2017. Antimicrob Resist Infect Control. 2019:8:90. doi: 10.1186/s13756-019-0539-x.
- Nikoloudi M, Eleftheriadou I, Tentolouris A, Kosta OA, Tentolouris N. Diabetic foot infections: update on management. *Curr Infect Dis Rep.* 2018;20(10):40. doi: 10.1007/s11908-018-0645-6.

**Cite this article:** Bindhu J, Umashankar R, Vasudevan R, Mahalakshmi B, Bagchi S, Kapfo W et al. Evaluating diagnostic approaches for diabetic foot infections: A systematic review. *IP Int J Med Microbiol Trop Dis.* 2025;11(1):9-23.